Rhabdomyosarcoma is a rare childhood cancer that arises in muscle stem cells. Between 250-350 cases are treated each year. The disease most commonly begins as a noticeable swelling in the arms, legs, head, neck, or groin, and is treated by surgical removal of the tumor, as well as chemotherapy or irradiation. Currently, about 80% of patients diagnosed with rhabdomyosarcoma survive, as the disease is often caught early enough for intervention.
In this feature, one senior investigator, one junior investigator, and one postdoctoral researcher—all working...
Read more about An HSCI approach to rhabdomyosarcoma 
The 
Harvard Stem Cell Institute (HSCI) researchers have a new model for how the kidney repairs itself, a model that adds to a growing body of evidence that mature cells are far more plastic than had previously been imagined.... 
Harvard Stem Cell Institute (HSCI) researchers have settled a century-old debate over whether occurrence of DNA methylation acts to silence gene expression, or if genes are turned off by other means before they are methylated.
Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute (HSCI) researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation. This milestone, just nine short years after Harvard’s major commitment to stem cell biology, once again demonstrates the ability of HSCI investigators to carry a discovery from the lab bench to the clinic—fulfilling the promise on which the Institute was founded.... 
More than 15 years after the discovery of kidney injury molecule-1 (KIM-1) by 
A group of Brigham and Women’s Hospital, and Harvard Stem Cell Institute researchers, and collaborators at MIT and Massachusetts General Hospital have found a way to use stem cells as drug delivery vehicles.
Harvard Stem Cell Institute (HSCI) scientists have identified a new therapeutic approach for treating